Memorial Sloan Kettering Cancer Center

We're excited to share Memorial Sloan Kettering Cancer Center (MSK)'s bold new advertising campaign “This Is What We Do.” From a jazz musician whose life was saved by precision oncology, to a prostate cancer patient who has become an advocate for early detection, the stories we share throughout this campaign reflect our shared mission and the extraordinary outcomes we achieve together. 🔹 This is treatment on a cellular level. ​ 🔹 This is care on a personal level. ​ 🔹 This is hope on another level. ​ When someone receives a cancer diagnosis, we want them to know exactly what to do next: come to MSK. And when patients choose MSK, they’re choosing better, longer lives. Learn more: bit.ly/3SgwqKj

Screening nonsmokers with family history: Dr. Jamie Chaft (@MSKCancerCenter) reviews LUNG-CARE and TALENT data, the adenocarcinoma in situ question, and Sybil AI via LEGACY trial, and concluded that there is no role for early screening in the US today. #DAVALung

The @US_FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial #sarcoma. The clinical trials resulting in the drug’s approval were led by MSK sarcoma specialist and immunotherapy expert Dr. @sandrapdangelo. “This treatment offers a meaningful new option for people with this rare cancer,” Dr. D’Angelo says. “It is also an important step forward in the development of T cell therapies for solid tumors, which has been a major challenge.” Read more about this treatment: bit.ly/4fvX36j

We’re pleased to announce an inaugural two-day virtual symposium @MSKCancerCenter highlighting the latest advances in surgical oncology across the cancer care continuum. Explore perioperative optimization, minimally invasive approaches, enhanced recovery, complex surgical emergencies, technology and innovation, workforce development, and health equity. Attend live October 28–29 or register for on demand access. Learn more: bit.ly/SurgOnc2026

New research from MSK investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; and more: bit.ly/4vqky6I

Congratulations @CowzerDarren. Great deep dive #biliarytractcancer #genomics outcomes and resistance! @MSK_DeptOfMed @MSKCancerCenter @MskccCMO @DSolit @GABOUALFA @EileenMOReilly

Today, we’re celebrating the strength of our MSK patients, families, caregivers, and staff alike. Wishing you a safe and meaningful Fourth of July. 🇺🇸

Thrilled 🤩 to join this 🔋Powerhouse session at #ESMOGI2026. Incredible to witness so many advances in pancreatic cancer presented on one stage and to share it with leaders including Brian Wolpin, Nilo Azad, Eric Van Cutsem and @MacarullaTeresa The era of K/RAS inhibitors, rational combinations and biomarker-driven therapeutics is here. #daraxonrasib #zoldonrasib Unprecedented response rates in this disease ever! We keep learning from the positive and negative work. Search and REsearch! I really appreciate the team so dedicated to learn the science from the #GLEAM trial #CLDN18 #zolbetuximab We’re finally moving the field forward. The future of pancreatic cancer has never looked brighter 💡 #PancreaticCancer #KRAS #RAS #TeamScience @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @PanCAN @letswinpc @Pankind_Aus @OncoAlert @OncBrothers @oncodaily @OncoDailyGI @NatPancFdn

Team science 🧬 at its best. Great to catch up with the MSK family and honorary MSK friends at #ESMOGI26 The future of GI oncology will be built through collaboration, bold ideas and friendships that span institutions and continents. Onward. #PancreaticCancer #GIOncology #KRAS #RAS #CLDN18 #TranslationalResearch #GRIT @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @myESMO @EileenMOReilly @BenWestphalen @graokane @BasGrootKoerkam @nasca_vincenzo @wei_ac

Advances in #prostatecancer care are making treatment more personalized than ever. At MSK, experts evaluate each person's disease to better understand their level of risk, helping guide treatment decisions while offering advanced surgery, radiation therapy, targeted therapies, and clinical trials when needed. “At MSK, we’ve made many advances in prostate cancer treatment,” says MSK’s Dr. Massimiliano Spaliviero. “But just as important, we developed more personalized evaluations to better understand each person’s disease.” Learn more: bit.ly/4eWThCA

#CART cell therapy shows promise in treating #precancers like smoldering myeloma, but requires careful patient selection due to potential risks. News & Views from Sham Mailankody & Eric Jurgens @MSKCancerCenter. dlvr.it/TTJKw8

New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: bit.ly/443KBp2

Could CAR T redefine treatment for AL #amyloidosis? 💡 Heather J. Landau, MD (@MSKCancerCenter) discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis. 🎥 Watch: targetedonc.com/view/rapid-hem… #Hematology #Oncology

🚨 The @US_FDA has approved datopotamab deruxtecan (Dato-DXd) for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy. The approval was based on results from the international Tropion-Breast02 clinical trial, led in the U.S. by MSK breast medical oncologist Dr. Tiffany Traina. Learn more: bit.ly/3SlkVS9

Spotlighting research from MSK gynecologic medical oncologist and #ASCO26 Conquer Cancer grant recipient @AliSchram ⬇️

MSK researchers are helping advance #MorPhiC, an international effort to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome. The work aims to transform the human genome from a list of parts into an instruction manual, helping researchers better understand what our genes do and how they shape human development. Learn more about how MSK researchers are contributing to this effort: bit.ly/4g2n8Ma

Now in @CD_AACR: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @SawyersLabMSKCC, @nikolausschultz, et al. @MSKCancerCenter - these findings suggest that the previously reported survival advantage may be explained by selection bias.

Already giving patients daraxonrasib off trial only 21 days after the practice-changing results were presented at @ASCO 2026. Thank you to @MSKCancerCenter and @RevMedicines for allowing us to fill this unmet need safely and efficiently. @EileenMOReilly @CentralParkWMD @CpcrMsk

To Linds: I love you, and I never blinked. Lindsay rang the bell at 10:55AM EST at @MSKCancerCenter. 4 months- unexpected diagnosis, surgery, radiation… behind us because you are a champion. To all who are fighting, or know someone who is… we see you. We support you.

📚 🚀Catch up on the latest insights in Multiple Myeloma from our session with Saad Z. Usmani, MD (@szusmani) and Adeel Khan, MD (@khancology)! ➡️Watch the full session: youtu.be/5Nt9T02Fyy4?si… #MultipleMyeloma #PlasmaCellDisorders #Hematology #Oncology #MedicalEducation #PatientCare #Immunotherapy #CellTherapy #NovelTherapies #ClinicalTrials #HemeHub #HematologyEducation @MSKCancerCenter @UTSWHemeOnc @MM_Hub @llmcongress @theMMRF @RareDiseases

A new study by @RShouval and team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @MSKCancerCenter Learn more: bit.ly/4vYu0yL